超声介入聚桂醇硬化剂治疗肝囊肿疗效的分析

Analysis of the Efficacy of Ultrasound-Guided Lauromacrogol in the Treatment of Hepatic Cyst

目的:探讨超声介入聚桂醇硬化剂治疗肝囊肿疗效的疗效。方法:将在我院76例被确诊为肝囊肿患者,随机分成治疗组(n=38)和对照组(n=38),治疗组在超声介入下囊肿内注入聚桂醇注射液,对照组采用乙醇治疗,比较两组住院时间、住院总费用、疗效以及不良反应。结果:治疗组患者抽出液(81.57±5.86)ml,对照组患者抽出液(91.71±7.80)ml,两组抽出液的差异有显著性(p<0.05);治疗组和对照组患者住院时间分别为(4.86±0.90)天、(7.29±1.38)天,两组住院时间差异有显著性(P<0.05);治疗组住院总费用为(4580.14±945.01)元,对照组患者住院总费用分别(4965.86±796.72)元;两组住院总费用差异无显著性(P>0.05);治疗组总有效率为94.74%,对照组总有效率为81.58%,两组临床治疗效果差异有显著性(P<0.05);两组患者不良反应发生例数无统计学差异(P>0.05)。结论:聚桂醇作为新型硬化剂,疗效较好,不良反应少,可以成为囊肿超声介人治疗的首选硬化剂。

Objective： to explore the clinical effect of ultrasound-guided lauromacrogol in the treatment of hepatic cyst. Methods： 76 patients with hepatic cyst were divided randomly into two groups. The treating group（n=38） were treated with thelauromacrogol injec- tion, while the control group （n=38） was given with ethanol. Comparing the curative effect, total cost, hospital stays and the side effect between two groups. Results： the extract in the treating group and control group is （81.57± 5.86）ml, （91.71± 7.80）ml respectively, which was statistical （P〈0.05）; the hospital stays in the treating group is （4.86± 0.90）d, which was statistical to compare that（7.29± 1.38） in the control group（P〈0.05）; however, there is no statistical difference comparing the total cost between two groups（P〉0.05）; the total effective rate in the treating group is 94.74%, which is higher than that （81.58%） in the control group（P〈0.05）; there was no statistical difference of the cases of side effect between two groups （P〉0.05）. Conclusion： Lauromacrogol is a new hardener characterized with good curative effeet, less side effect, which can be the first choice to ultrasound intervention to treat hepatic cyst.